193. Prader-Willi syndrome Clinical trials / Disease details
Clinical trials : 113 / Drugs : 111 - (DrugBank : 26) / Drug target genes : 48 - Drug target pathways : 102
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2000040947 | 2021-01-01 | 2020-12-16 | The safety and effectiveness of rapamycin (sirolimus) in the treatment of Prader-Willi syndrome | The safety and effectiveness of rapamycin (sirolimus) in the treatment of Prader-Willi syndrome | Prader-Willi syndrome | rapamycin group:rapamycin 1mg qd po; | Peking Union Medical College Hospital | NULL | Recruiting | Both | rapamycin group:30; | China |